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Abstract
Smoking is one of the most impactful lifestyle-related risk factors in many cancer types including esophageal squamous cell
carcinoma (ESCC). As the major component of tobacco and e-cigarettes, nicotine is not only responsible for addiction to
smoking but also a carcinogen. Here we report that nicotine enhances ESCC cancer malignancy and tumor-initiating
capacity by interacting with cholinergic receptor nicotinic alpha 7 subunit (CHRNA7) and subsequently activating the
JAK2/STAT3 signaling pathway. We found that aberrant CHRNA7 expression can serve as an independent prognostic
factor for ESCC patients. In multiple ESCC mouse models, dextromethorphan and metformin synergistically repressed
nicotine-enhanced cancer-initiating cells (CIC) properties and inhibited ESCC progression. Mechanistically, dextromethor-
phan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by
antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Since dextromethorphan and metformin are
two safe FDA-approved drugs with minimal undesirable side-effects, the combination of these drugs has a high potential as
either a preventive and/or a therapeutic strategy against nicotine-promoted ESCC and perhaps other nicotine-sensitive cancer
types as well.
Introduction
Tobacco smoking is one of the most impactful risk factors
for many malignancies with nicotine being the major
ingredient responsible for the development of addiction to
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both tobacco consumption and nicotine-based e-cigarettes
[1–3]. Apart from potentially causing immediate harm to
adolescent health, nicotine consumption also sows the seeds
for future problems by predisposing consumers to substance
abuse [4, 5]. More recent evidence suggests that nicotine as
well as its metabolites such as nitrosamine ketone can
induce DNA damage and hinder DNA damage repair [6].
However, the carcinogenic effects of nicotine, as well as the
underlying molecular mechanisms, are not fully delineated
[7, 8], and this is part of the reason for a lack of effective
therapeutic agents to blockade the detrimental effect of
nicotine in the context of malignancy.
Nicotine exerts its biological effects mainly via the
nicotinic acetylcholine receptors (nAChRs) [9, 10]. The
functional nAChRs comprise homopentamers of α-subunits
or heteropentamers with at least one α- and one β-subunit.
In mammals, seven α subunits (CHRNA2 to CHRNA7,
CHRNA9, and CHRNA10), four β (CHRNB1 to CHRNB4),
and one each of subunits δ (CHRND), ε (CHRNE), and γ
(CHRNG) have been identified. Multiple lines of evidence
indicate that homopentameric nAChRs of CHRNA1,
CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, and
CHRNA9 are involved in cancer initiation and progression
[11–15]. Among them, CHRNA7 and CHRNA9 have been
reported to be capable of inducing cancer stem cell-like
cells (CSC) or cancer-initiating cells (CIC) [16–18].
Therefore, targeting these nAChRs could potentially inhibit
nicotine-induced tumor initiation.
Esophageal squamous cell carcinoma (ESCC) is the 6th
leading cause of cancer-related mortality worldwide and the
CICs are critical for malignancy, drug resistance, and
recurrence [19–22]. Both environmental and lifestyle-
related factors, such as nicotine consumption play impor-
tant roles in ESCC initiation and progression [19–22]. By
using ESCC as a model system with both in vitro and
in vivo approaches, we demonstrated that nicotine is cap-
able of enhancing ESCC CIC properties by activating the
CHRNA7/JAK2/STAT3/SOX2 axis. More importantly,
two FDA-approved drugs dextromethorphan and metformin
at their pharmacological doses can synergistically inhibit
nicotine-enhanced CIC properties and ESCC progression.
Results
Nicotine enhances tumor-initiating properties
through CHRNA7
To determine if nicotine played any role in tumors other
than lung cancer, we first conducted gene set enrichment
analysis (GSEA) and revealed that in human ESCC the CIC
signature was highly correlated with cigarette smoking
(Fig. 1a). We then treated two human ESCC cell lines
KYSE270 and TE1 with different concentrations (0.1, 1,
and 10 μM) of nicotine, and found that treatment with
nicotine decreased the levels of both cytokeratin 14 (CK14)
and CK18 in a dose-dependent manner, drastically at 10 μM
(Fig. 1b). In addition, we found that nicotine is also capable
of increasing both the number and the size of ESCC
tumorspheres in 3D culture (Fig. 1c). Since mecamylamine,
an antagonist of the nAChRs, is capable of counteracting
nicotine-enhanced sphere formation (Fig. 1c), we postulated
that nicotine acted on ESCC through nAChRs. Flow cyto-
metry analyses showed that nicotine treatment significantly
increased percentages of two CIC markers, ALDH+ cells
(Fig. 1d) and CD44+ cells (Fig. 1e), and these effects were
blocked by mecamylamine (Fig. 1d, e). These observations
collectively indicate that nicotine can enhance tumor-
initiating properties in human ESCC cells likely through
one or more nAChR.
We then want to determine which subunit (s) of nAChRs
is responsible for nicotine-enhanced CIC properties.
Although the levels of CHRNA1, CHRNA5, CHRNA6,
CHRNA7, CHRNA9, CHRNB1, CHRNB3, and CHRNB4
in ESCC were all significantly higher than that of the nor-
mal esophageal tissues (Fig. 2a), results from GSEA indi-
cate that only CHRNA5 and CHRNA7 were associated with
CIC properties in ESCC patients (Fig. 2b–i). Nevertheless,
when ESCC cells were treated with nicotine, the mRNA
levels of CHRNA7, but not CHRNA5, is upregulated
(Fig. 2j, k). In addition, compared with that in immortalized
esophageal cell lines, the protein levels of CHRNA7 are
significantly higher in all the ESCC cell lines tested
(Fig. 2l). Based on these observations, we postulated that
CHRNA7 may play a more important role in nicotine-
induced CIC properties.
To determine the clinical relevance of CHRNA7 in
ESCC, we analyzed a tissue microarray with ESCC speci-
mens and their non-cancerous surrounding tissues from 104
patients and found that cells in ESCC tissues expressed
significantly higher levels of CHRNA7 than that of non-
tumorous tissues (P < 0.001, Wilcoxon matched-pair
signed-rank test; Fig. 3a). Receiver operator characteristic
analysis identified an optimal cutoff score of 7.583 for IHC
score, which categorized 50.96% (53 of 104) patients with
CHRNA7 overexpression. The clinicopathological char-
acteristics of this cohort were compared between cases with
high (above cutoff score) and low (at or below cutoff score)
CHRNA7 expression (Supplementary Table 1). We found
that high expression of CHRNA7 is highly correlated with
lymph node metastasis (P= 0.010), tumor stage (P=
0.019), and smoking history (P= 0.048). Notably, the
CHRNA7 levels in ESCC specimens in a majority of
smokers are higher than their respective non-cancerous
surrounding tissues (Fisher exact test; P= 0.018, Supple-
mentary Fig. 1a). Kaplan–Meier analysis revealed that
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patients with high CHRNA7 expression were associated
with a significantly shorter overall survival (median:
34.9 months) than those with low CHRNA7 expression
(median: 46.4 months) (log-rank test; P= 0.008, Fig. 3b).
Univariate and multivariate Cox regression analyses indi-
cate that high CHRNA7 expression is a significant
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prognostic factor for overall survival (hazard ratio 1.903;
confidence interval 1.061–3.414; P= 0.031, Supplementary
Table 2). Consistently, the RNAseq data derived from 95
ESCC patients in TCGA dataset (TCGA-ESCA) also
showed a significant association between CHRNA7
expression and ESCC prognosis (log-rank test; P= 0.025,
Supplementary Fig. 1b). More importantly, nicotine treat-
ment upregulated both mRNA and protein levels of
CHRNA7 in the ESCC cells (Fig. 3c). Since the expression
of CHRNA7 is higher in tumorspheres (Supplementary Fig.
2a), and knocking down CHRNA7 (Supplementary Fig. 2b)
not only reduced the size of the spheres but also the number
of CD44+ cells (Supplementary Fig. 2c), we conducted flow
cytometry assays and demonstrated that knocking down
CHRNA7 attenuated the nicotine-induced subpopulation of
both ALDH+ (Fig. 3d) and CD44+ cells (Fig. 3e). These
data altogether demonstrate that CHRNA7 plays an
important role in the nicotine-enhanced CIC properties of
ESCC.
Nicotine enhances CIC properties through the
CHRNA7/JAK2/STAT3/SOX2 axis
The exact molecular mechanisms in CHRNA7-mediated
downstream signaling pathways are far from fully defined
[23, 24]. Since our GSEA analysis found that CHRNA7
expression is associated with JAK2-STAT3 signaling in
different cancers (Supplementary Fig. 2d), we test the
hypothesis that nicotine enhances tumor-initiating capacity
by activating CHRNA7 and subsequently the JAK2/STAT3
pathway. Since knockdown and overexpression CHRNA7
in two ESCC cells reduced or enhanced phosphorylation of
JAK2 (p-JAK2) and STAT3 (p-STAT3), respectively,
without affecting the total levels of these factors (Supple-
mentary Fig. 2e), we examined the correlation between
CHRNA7 and CIC-associated markers in a GEO database
(GSE47404) and found that CHRNA7 expression is highly
associated with SOX2 (r= 0.6812, P < 0.001) and NANOG
(r= 0.2689, P= 0.023) (Supplementary Fig. 2f). Given the
well-established role of SOX2 in tumor-initiating cells, we
experimentally demonstrated the parallel relationship
between CHRNA7 and SOX2 when CHRNA7 is either
knocked down or overexpressed (Supplementary Fig. 2e).
Interestingly, protein–protein interaction network analysis
(STRING) suggests that CHRNA7 interact with CSC
associated proteins through STAT3 (Supplementary Fig.
2g). In addition, compared with control (left), strong Duo-
link signals in cells treated with nicotine (right) were
observed in a proximity ligation assay using antibodies
against CHRNA7 and JAK2 (Supplementary Fig. 2h).
These data altogether suggest that nicotine-activated
CHRNA7 may interact with JAK2 at first and subse-
quently activates the STAT3/SOX2 pathway.
To further substantiate the role of the CHRNA7-
regulated JAK2/STAT3/SOX2 axis in CIC properties, we
inoculated different numbers of cells harboring over-
expressed CHRNA7 (Fig. 4a) into the flank of nude mice.
The overexpressed CHRNA7 was capable of not only
enhancing tumor formation (Fig. 4b) but also generating
bigger tumors (Fig. 4c). Notably, only CHRNA7-
overexpressing cells formed tumors when a small number
(5 × 103) of cells were implanted (Fig. 4c). Also, western
blotting (Fig. 4d) and IHC (Fig. 4e) showed that over-
expressed CHRNA7 not only activated the JAK2/STAT3
pathway but also increased CIC properties evidenced by
increased CD44 and SOX2. Consistent with the results from
the patients (Supplementary Table 1), CHRNA7 over-
expression led to an increase of metastatic lesions in the
lymph node (Supplementary Fig. 3a). Interestingly,
CHRNA7 overexpression enhanced the CIC properties of
metastatic cells in the lymph node, as evidenced by
CD44 staining (Supplementary Fig. 3b). These data alto-
gether suggest that nicotine enhances tumor-initiating
capacity in primary tumors and metastatic lesions by tar-
geting the CHRNA7/JAK2/STAT3/SOX2 axis.
Metformin counteracts nicotine-upregulated
CHRNA7 by enhancing promoter hypermethylation
To explore whether inhibiting CHRNA7 expression or
repressing its activity could be an efficacious therapeutic
strategy, we first conducted bioinformatics analyses of the
publicly available dataset with 95 human ESCC samples in
cBio Cancer Genomics Portal (http://cbioportal.org) but
failed to identify any mutation, deletion, fusion or two cases
of amplification of CHRNA7 in this dataset (Supplementary
Fig. 4a). However, by analyzing the methylation status of
CHRNA7 gene in two independent ESCC microarray
datasets (GSE20123 and GSE52826), we found that DNA
methylation of CHRNA7 promoter in ESCC cells was
Fig. 1 Nicotine induces ESCC CIC properties by activating nico-
tinic acetylcholine receptor. a Gene set enrichment analysis (GSEA)
of enrichment of MUELLER_PLURINET in nonsmoking patients vs.
smoking patients in GSE53625 dataset. FDR false-discovery rate q
value. NES normalized enrichment score. b Representative images of
immunofluorescence for CK14 and CK18 in KYSE270 cells (upper
panel) and TE1 cells (bottom panel) treated with different concentra-
tions (0.1, 1, and 10 μM) of nicotine for 48 h. c Representative images
of spheres formed by KYSE270 and TE1 cells treated with nicotine
alone or combined with mecamylamine (left panel). Quantification of
spheres formed per 1000 cells (right panel). d Flow cytometry analysis
of the ALDH-positive population in TE1 cells treated with nicotine or
mecamylamine. e Flow cytometry analysis of the CD44-positive
population in TE1 cells treated with nicotine or mecamylamine. Data
are shown as the means of three independent experiments or repre-
sentative data. Error bars indicate SD. **P < 0.01, ***P < 0.001 by
Student’s t-test or one-way ANOVA with post hoc intergroup
comparisons.
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significantly (P < 0.001 and P < 0.01, respectively) lower
than that in the normal tissues (Supplementary Fig. 4b).
Since it has been reported that metformin is capable of
increasing DNA hypermethylation [25–27] and we have
previously demonstrated that metformin possesses anti-
neoplastic property toward ESCC [21, 28, 29], we decided
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to explore (1) if metformin can inhibit nicotine-induced
CIC traits, (2) whether nicotine upregulates CHRNA7 in
ESCC cells by altering promoter DNA methylation of
CHRNA7 gene, and if so, (3) whether metformin can
downregulate CHRNA7 by counteracting nicotine-
mediated hypomethylation.
We first examined the effect of metformin on nicotine-
induced CIC properties of ESCC cells and immortalized
non-malignant esophageal cell line (NE2) cultured in 2D
and 3D conditions in the presence of different concentra-
tions of metformin. Low concentration (between 0.6 and
1.0 mM) of metformin could inhibit the proliferation of 3D
cultured cancer cells with minimal effect on either non-
cancer cells or 2D cultured cancer cells (Fig. 5a). To
demonstrate the role of CHRNA7 in metformin-inhibited
CIC properties, we estimated the mRNA (Fig. 5b) and
protein (Fig. 5c) levels of CHRNA7 in two ESCC cancer
cell lines, when they were treated with metformin (0.8 mM)
and nicotine alone or in combination. We found that met-
formin can downregulate both basal level and nicotine-
enhanced CHRNA7 expression. Metformin was also cap-
able of inhibiting CHRNA7-mediated spheroid formation
and growth (Fig. 5d). These data demonstrated that phar-
macologically achievable concentrations of metformin can
suppress nicotine-induced CIC traits, likely through
repression of CHRNA7. Next, we investigated (1) if
nicotine-upregulated CHRNA7 is promoter hypomethyla-
tion-dependent, and (2) if metformin can downregulate
CHRNA7 by counteracting nicotine-mediated hypomethy-
lation. MassARRAY [26, 30] showed that nicotine down-
regulated DNA methylation of the CHRNA7 promoter
region significantly (P < 0.01), and metformin counteracted
nicotine-mediated hypomethylation (Fig. 5e). Further ana-
lyses pinpointed the methylation sites were clustered
between −119 and −141 above the CHRNA7 transcription
starting site (Fig. 5f). These data suggest that metformin
counteracts nicotine-induced ESCC progression by block-
ing CHRNA7 promoter hypomethylation.
Dextromethorphan suppresses nicotine-induced CIC
properties of ESCC by non-competitive inhibition of
CHRNA7
By examining the publicly available data in DrugBank
(https://www.drugbank.ca/drugs/), we found that CHRNA7
could be inhibited by dextromethorphan, one of the most
widely used over-the-counter cough suppressants (Supple-
mentary Fig. 5). It has been reported that dextromethorphan
could potentially target different members of the nAChR
family including CHRNA2, CHRNA3, CHRNA4,
CHRNA7, and CHRNB4. But as a non-competitive
antagonist of CHRNA7, dextromethorphan can attenuate
nicotine’s antinociceptive and reinforcing effects at a rela-
tively low dosage [31, 32]. We then examined if dex-
tromethorphan can inhibit nicotine-induced ESCC tumor-
initiating capacity. Two ESCC cell lines were treated with
either 10 μM nicotine alone or in combination with different
concentrations (10, 20, 30, or 40 μM) of dextromethorphan
and found that dextromethorphan at a concentration of 30 or
40 μM is capable of counteracting nicotine-enhanced CIC
properties (Fig. 6a, b). In addition, dextromethorphan
(30 μM) can counteract nicotine-induced ESCC sphere
formation (Fig. 6c). To understand the underlying
mechanism, binding assays of [13C]-nicotine in over-
expressed CHRNA7 HEK293 cells with or without dex-
tromethorphan (30 µM) indicated that dextromethorphan
antagonized nicotine binding as a non-competitive inhibitor
(Fig. 6d).
Metformin and dextromethorphan inhibit nicotine-
induced tumor-initiating capability synergistically
Given the different mechanisms in metformin- and
dextromethorphan-counteracted nicotine-induced ESCC
tumor-initiating capacity, we expected that combination of
these drugs could inhibit nicotine-induced ESCC develop-
ment more efficiently. Indeed, results from both sphere
formation of TE1 and KYSE270 cells (Supplementary Fig.
6a) and flow cytometry (Fig. 7a, Supplementary Fig. 6b)
indicate that a combination of metformin and dex-
tromethorphan inhibited nicotine-induced CIC properties
more efficiently than either of them individually. Notably, a
combination of these drugs appeared to synergistically
counteract nicotine-induced expression of CHRNA7, as
well as downstream signaling in terms of p-JAK2, p-
STAT3, and SOX2 (Supplementary Fig. 6c). To demon-
strate that metformin and dextromethorphan counteract
nicotine-induced CIC properties synergistically in vivo, we
used two models, the 4-nitroquinoline N-oxide (4NQO)-
Fig. 2 CHRNA7 is closely correlated with ESCC CIC properties.
a The mRNA levels of the 12 nicotinic acetylcholine receptors derived
from an ESCC dataset in GEO (GSE53625), which includes 179
ESCC (tumor) and their paired adjacent normal tissues (nontumor).
The red and gray lines connect the nontumor and tumor values in
patients with high and low expression, respectively. GSEA plots of
enrichment of MUELLER_PLURINET in high expression versus low
expression of CHRNA1 (b), CHRNA5 (c), CHRNA6 (d), CHRNA7
(e), CHRNA9 (f), CHRNB1 (g), CHRNB3 (h), CHRNB4 (i) in the
GSE53625 dataset. FDR false-discovery rate q value. NES normalized
enrichment score. j The mRNA levels of CHRNA5 in KYSE270 and
TE1 cells treated with nicotine or vehicle. k Representative images of
semi-quantitative PCR analysis of CHRNA5 and CHRNA7 in
KYSE270 and TE1 cells treated with or without nicotine. GAPDH was
used as an internal loading control. l Immunoblotting analyses of
CHRNA7 expression in ESCC cell lines and immortalized normal
esophageal epithelial cell lines. Data are shown as the means of three
independent experiments or representative data. Error bars indicate
SD. *P < 0.05, **P < 0.01, ***P < 0.001 by paired t-test.
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induced ESCC mouse model and the nude mice carrying a
human ESCC xenograft. Compared to single-agent treat-
ment, co-administration of dextromethorphan, and
metformin dramatically decreased the tumor formation (i.e.,
tumor number per mouse and individual tumor size) in
nicotine-treated 4NQO-induced ESCC mice (Fig. 7b–d).
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IHC analysis showed that, among the experimental groups,
the combination of metformin and dextromethorphan
resulted in the greatest inhibition of the CHRNA7-JAK2-
STAT3 axis and the maximum reduction of the CIC mar-
kers (Supplementary Fig. 6d). Either single or combination
treatment, these two FDA-approved drugs exhibited mini-
mal undesirable side-effects (Supplementary Fig. 6e). In the
nude mouse model, nicotine markedly accelerated ESCC
tumor growth (Fig. 7e). Although either dextromethorphan
or metformin alone is capable of inhibiting nicotine-induced
tumor growth to a certain degree, a combination of them
almost completely ablated nicotine-enhanced cancer cell
growth (Fig. 7e, Supplementary Fig. 7a) and tumor weight
(Fig. 7f). Of note, IHC (Supplementary Fig. 7b) and western
blotting (Supplementary Fig. 7c) showed that the combi-
nation of dextromethorphan and metformin suppressed the
CHRNA7-JAK2-STAT3 axis more than either one alone in
Fig. 3 Upregulated CHRNA7 is associated with poor prognosis
and correlates with CIC properties. a Immunohistochemistry (IHC)
of CHRNA7 in 104 human ESCC tissues and their paired adjacent
normal tissues (left panel). Bar charts showing the percentage of cases
with different levels of CHRNA7 in tumors and their paired adjacent
normal tissues (right panel). b Kaplan–Meier curves compared the
overall survival in ESCC patients with high and low protein levels of
CHRNA7. c RT-qPCR (left panel) and immunoblot (right panel)
analysis of CHRNA7 in KYSE270 and TE1 cells treated with nicotine
or vehicle. GAPDH was used as an internal control. d Flow cytometry
analysis of ALDH-positive population in TE1 cells transfected with
shCHRNA7 #1 or shCtrl were treated with or without nicotine (top
panel). Histograms showing the proportion of ALDH-positive cells
(bottom panel). e Flow cytometry analysis of CD44-positive popula-
tion in TE1 cells transfected with shCHRNA7 #1 or shCtrl were
treated with or without nicotine (top panel). Histograms showing the
proportion of CD44-positive cells (bottom panel). Data are shown as
the means of three independent experiments or representative data.
Error bars indicate SD. **P < 0.01, ***P < 0.001 by Wilcoxon
matched-pair signed-rank test or one-way ANOVA with post hoc
intergroup comparisons.
Fig. 4 The effect of CHRNA7
on ESCC CIC properties
in vivo. a RT-qPCR (top panel)
and immunoblot (bottom panel)
analysis of CHRNA7 in
KYSE510 cells transfected with
CHRNA7 overexpression
plasmid or empty vector.
GAPDH was used as an internal
control. b The table showing
that the P value of each case in
which the nude mice (n= 8 per
group) were injected with
KYSE510 cells transfected with
CHRNA7 overexpression
plasmid or empty vector. c
Tumors derived from nude mice
injected KYSE510 cells stably
transfected with CHRNA7-
expressing plasmid or empty
vector at the end of the
experiments. d Immunoblot of
CHRNA7-JAK2-STAT3-SOX2
in representative tumors derived
from nude mice injected
KYSE510 cells stably
transfected with CHRNA7-
expressing plasmid or empty





expressing plasmid or empty
vector. GAPDH was used as an
internal control. Data are shown
as the means of three
independent experiments or
representative data. Error bars
indicate SD. ***P < 0.01 by
Student’s t-test.
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ESCC xenografts. Consistently, a combination of these
drugs suppressed ALDH- (Fig. 7g) and CD44-positive cells
(Supplementary Fig. 7d) synergistically. These data alto-
gether demonstrate that a combination of dextromethorphan
and metformin counteract nicotine-induced tumor initiation
capability synergistically and repress nicotine-induced
cancer progression efficiently.
Discussion
We identified a potentially effective strategy for treating
nicotine-induced cancer growth and progression using two
FDA-approved drugs, dextromethorphan and metformin,
with long safety records. We used ESCC, nicotine-related
cancer, as a model system to demonstrate that the combi-
natory therapy synergistically inhibits nicotine-enhanced
CIC properties by targeting CHRNA7. Our studies reveal
that CHRNA7, a nicotine-enhanced receptor, confers high
oncogenic potential by inducing CIC properties and serves
as a predictor of poor prognostic in ESCC. We have pro-
vided multiple lines of evidence derived from two ESCC
mouse models, patient sample analysis, bioinformatics
analyses, and cellular studies to indicate that CHRNA7 is
the specific receptor subtype responsible for nicotine-
enhanced CIC properties in ESCC. Our results derived
from bioinformatics analyses, in vivo and in vitro studies
and clinical data indicate that CHRNA7 mediates nicotine-
induced ESCC tumor-initiating capacity at least in part via
activating the JAK2/STAT3/SOX2 signaling pathway,
which has been proven to be frequently dysregulated in
human ESCC [33]. Accordingly, using dextromethorphan
and metformin together is an effective strategy to block
CHRNA7/JAK2/STAT3/SOX2 signaling (Fig. 8).
Fig. 5 Metformin downregulates CHRNA7 by enhancing its pro-
moter DNA hypermethylation to repress ESCC CIC properties.
a Cell survival curves of NE2, adherent- or sphere-cultured TE1 cells
treated with metformin at the indicated concentrations. b, c The
mRNA and protein levels of CHRNA7 in KYSE270 and TE1 cells
treated with vehicle, metformin (Met) for 48 h, Met for 72 h, nicotine
(Nic) for 24 h, Met for 48 h followed by the combination of Met and
Nic for 24 h. GAPDH was used as an internal control.
d Representative images of spheres formed by TE1 cells transfected
with CHRNA7 or vector treated with or without metformin. e The
methylation level of CHRNA7 in TE1 cells treated with vehicle, Nic,
Nic, and Met. f The methylation status on ten CpG islands in TE1 cells
treated with vehicle, Nic, Nic, and Met. Data are shown as the means
of three independent experiments or representative data. Error bars
indicate SD. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t-test or
one-way ANOVA with post hoc intergroup comparisons.
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Given that CHRNA7 lacks genetic alterations, such as
amplification but is rich in DNA methylation in its promoter,
we conducted a series of in vitro and in vivo experiments
proving that metformin can inhibit nicotine-induced CIC traits
by counteracting nicotine-mediated DNA hypomethylation of
the CHRNA7 promoter. Indeed, our results are supported by
other reports that metformin is capable of enhancing DNA
hypermethylation in the breast, endometrial, and ovarian
cancer cells [26, 27, 34]. In contrast to metformin, dex-
tromethorphan, one of the most widely used over-the-counter
cough suppressants [35], has not been used in any anti-cancer
studies. However, dextromethorphan has been found to ben-
efit patients with Alzheimer’s disease and mitigate pain in
painful diabetic neuropathy and chemotherapy-induced per-
ipheral neuropathy [36–38]. Indeed, results from our animal
model demonstrated that metformin and dextromethorphan
alone can counteract nicotine-mediated ESCC progression
effectively. Interestingly, metformin and dextromethorphan
acted synergistically and almost completely abrogated
nicotine-mediated CIC properties and progression. To our
knowledge, we are the first to experimentally demonstrate that
(1) metformin and dextromethorphan can downregulate the
expression and inhibit the activity of CHRNA7, respectively,
and (2) combination of these reagents can counteract nicotine-
enhanced ESCC tumor-initiating capacity, and therefore
inhibit ESCC progression.
Fig. 6 Dextromethorphan inhibits ESCC CIC properties by non-
competitive inhibition of CHRNA7. a Flow cytometry analysis of
ALDH-positive population in TE1 cells treated with vehicle, 10 μM
nicotine, 10 μM nicotine and dextromethorphan (DM) (10, 20, 30, or
40 μM) for 48 h (top panel). Histograms showing the proportion of
ALDH-positive cells (bottom panel). b Flow cytometry analysis of
CD44-positive population in TE1 cells treated with vehicle, 10 μM
nicotine, 10 μM nicotine, and dextromethorphan (DM) (10, 20, 30, or
40 μM) (top panel). Histograms showing the proportion of CD44-
positive cells (bottom panel). c Representative images of spheres
formed by TE1-CHRNA7 or TE1-vector treated with 10 μM nicotine
and/or 30 μM dextromethorphan. d Saturation binding curves for
[13C]-nicotine specific binding to HEK293 cells stably transfected with
an overexpressed CHRNA7 plasmid with or without 30 µM dex-
tromethorphan. Data are shown as the means of three independent
experiments or representative data. Error bars indicate SD. **P < 0.01,
***P < 0.001 by Student’s t-test or one-way ANOVA with post hoc
intergroup comparisons. NS non-significant.
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In summary, our findings support the prognostic and
therapeutic importance of CHRNA7 in nicotine-induced
cancer-initiating properties, by showing that a combination
of dextromethorphan and metformin may serve as either a
preventive (e.g., secondary prevention) or therapeutic
strategy against nicotine-relevant cancers.
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Materials and methods
Cells and reagents
The human ESCC cell lines HKESC-2 and three human
immortalized esophageal epithelial cells (NE2, NE3 and
NE083) were kindly provided by Dr. SW Tsao (Uni-
versity of Hong Kong, China). The human ESCC cells
TE1 cells were kindly provided by Dr. XC Xu (M.D.
Anderson Cancer Center, Houston, TX, USA). The human
ESCC cells KYSE140, KYSE150, KYSE510, KYSE270,
and KYSE520 cells were obtained from the tumor cell
bank of the Chinese Academy of Medical Science. These
ESCC cells were cultured in DMEM or RPMI 1640
medium supplemented with 10% FBS 37 °C in a humi-
dified atmosphere with 5% CO2. Immortalized NE2, NE3
and NE083 cells were cultured in Defined Keratinocyte-
SFM medium (DK-SFM, Gibco). All cell lines have been
authenticated using short tandem repeat DNA profiling
(Beijing Microread Genetics Co., Ltd., China). Nicotine
and metformin were purchased from Sigma-Aldrich.
Dextromethorphan was purchased from MedChemEx-
press. [13C]-nicotine was purchased from Cambridge
Isotope Laboratories, Inc.
Gene set enrichment analyses
The ESCC dataset GSE53625 from GEO, breast invasive
carcinoma dataset, lung adenocarcinoma dataset, and colon
adenocarcinoma/Rectum adenocarcinoma Esophageal car-
cinoma dataset from TCGA database were analyzed using
GSEA software (Version 2.2.1, http://software.broa
dinstitute.org/gsea/index.jsp).
[13C]-Nicotine binding assay
Cells were cultured to 90% confluence and scraped. The
cells were then incubated in [13C]-nicotine alone or with
dextromethorphan at room temperature for 30 min followed
by 60 min at 4 °C. After incubation, cells were washed three
times using ice-cold PBS, vacuum dried and then wrapped
with a silver-cup. Samples were measured on Thermo Sci-
entific MAT253 (HT-IRMs). For the saturation binding
assay, 1, 10, 20, and 50 µM concentrations of [13C]-nico-
tine, with or without 30 µM of dextromethorphan, were
used to test the dissociation constant Kd and the maximal
binding capacity Bmax.
4NQO-induced carcinogenesis model
Six-week-old C57BL/6 mice (Vital River Lab Animal
Technology Co Ltd., Beijing, China) were given 100 μg/
mL carcinogen 4NQO (Cat. N8141, Sigma) in drinking
water for 16 weeks to induce ESCC. The mice were
randomized into five groups (n= 8 per group). To
investigate the effects of nicotine, metformin and dex-
tromethorphan on ESCC, nicotine (200 μmol/L), metfor-
min (160 mg/kg), or dextromethorphan (40 mg/kg) was
taken orally for 16 weeks and then the mice were eutha-
nized 12 weeks later. Animals were randomly assigned to
groups and no blinding was done. All the animal experi-
ments were approved by the Ethics Committee and the
Chancellor’s Animal Research Committee at SUMC
(SUMC2014-148).
Statistical analysis
All statistical analyses except for microarray data were
carried out using the statistical software package SPSS 17.0
(SPSS, Inc., Chicago, IL, USA). The comparisons between
two groups were performed with Student’s t-tests and those
among >2 groups with one-way ANOVA with post hoc
intergroup comparisons. The correlation between CHRNA7
expression and clinicopathologic data of patients was ana-
lyzed with the Pearson χ2 test. Survival curves were plotted
with the Kaplan–Meier method and compared by the log-
rank test. Survival data were evaluated by univariate and
multivariate Cox regression analyses. The correlations of
the histoscore between CHRNA7 and the indicated bio-
markers of ESCC were determined by Spearman’s rank test.
P value of less than 0.05 was considered statistically
significant.
Fig. 7 Dextromethorphan and metformin inhibit nicotine-induced
ESCC CIC properties synergistically. a The ALDH-positive popu-
lation in TE1 cells treated with vehicle, Nic, Nic and Met, Nic and
DM, or Nic, Met, and DM. b The protocol of chemical-induction of
esophageal squamous cell carcinoma in C57BL/6 mice. c Tumors per
mouse in the esophagus from mice treated with vehicle, Nic, Nic and
Met, Nic and DM, or Nic, Met, and DM. Red arrows indicate eso-
phageal tumors. d The number of tumors per mouse in the esophagus
from mice was plotted. Growth curves (e) and the weight (f) of tumors
derived from TE1 cells in nude mice treated with vehicle, Nic, Nic and
Met, Nic and DM, or Nic, Met, and DM. g The ALDH-positive
population in tumors derived from nude mice treated with vehicle, Nic,
Nic and Met, Nic and DM, or Nic, Met, and DM (left panel). Histo-
grams showing the proportion of ALDH-positive cells (right panel).
Data are shown as the means of three independent experiments or
representative data. Error bars indicate SD. *P < 0.05, **P < 0.01,
***P < 0.001 by Student’s t-test or one-way ANOVA with post hoc
intergroup comparisons. #Nic vs. vehicle, &Nic vs. Nic and Met, $Nic
vs. Nic and DM, and @Nic vs. Nic, Met, and DM; n= 8 per group;
error bars indicate SD; ##P < 0.01, ###P < 0.001; &P < 0.05, &&&P <
0.001; $$P < 0.01, $$$P < 0.001; @@@P < 0.001 by two-way ANOVA
followed by a Tukey-Kramer post hoc test.
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Additional details about materials and methods are
described in Supplementary Data.
Acknowledgements The work was supported by a grant in part by the
National Natural Science Foundation of China (82072683, 81773087,
81071736, 81572876, and 30973508 to HZ; 82002491 to LW); the
Natural Science Foundation of Guangdong Province of China
(9151018004000000 to HZ; 2020A1515110049 to LW); the Science
and Technology Planning Project of Guangdong Province of China
(2019A030317024 to HZ); Special Project on the Integration of
Industry, Education and Research of Guangdong Province
(2011A090100024 to HZ); China Postdoctoral Science Foundation
(2020M673078 to LW); Flagship specialty construction project-
General surgery (Funding no.: 711003).
Author contributions HZ conceived and designed the experiments.
DL and XX performed bioinformatics analyses. LW, DL, and XX
performed the in vitro experiments. LW, ZY, and SW performed the
in vivo experiments. LW, YL, and JZ performed and guided the sta-
tistical analysis. YG, YC, GK, and YP provided or collected the study
materials or patients. HZ, SJY, and DZ wrote the manuscript. All the
authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest The authors declare no competing interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Moerke MJ, McMahon LR, Wilkerson JL. More than smoke and
patches: the quest for pharmacotherapies to treat tobacco use
disorder. Pharmacol Rev. 2020;72:527–57.
2. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and
cessation for cancer survivors: an overview for clinicians. CA
Cancer J Clin. 2014;64:272–90.
3. Fillon M. Tobacco control initiatives cut the number of lung cancer
deaths in California by 28. CA Cancer J Clin. 2019;69:83–85.
4. El-Toukhy S, Baig SA, Jeong M, Byron MJ, Ribisl KM, Brewer
NT. Impact of modified risk tobacco product claims on beliefs of
US adults and adolescents. Tob Control. 2018;27:s62–9.
5. Kreslake JM, Wayne GF, Alpert HR, Koh HK, Connolly GN.
Tobacco industry control of menthol in cigarettes and targeting of
adolescents and young adults. Am J Public Health. 2008;98:1685–92.
6. Lee HW, Park SH, Weng MW, Wang HT, Huang WC, Lepor H,
et al. E-cigarette smoke damages DNA and reduces repair activity
in mouse lung, heart, and bladder as well as in human lung and
bladder cells. Proc Natl Acad Sci USA. 2018;115:E1560–9.
7. Zhang Q, Ganapathy S, Avraham H, Nishioka T, Chen C. Nico-
tine exposure potentiates lung tumorigenesis by perturbing cel-
lular surveillance. Br J Cancer. 2020;122:904–11.
8. Dennis PA, Van Waes C, Gutkind JS, Kellar KJ, Vinson C,
Mukhin AG, et al. The biology of tobacco and nicotine: bench to
bedside. Cancer Epidemiol, Biomark Prev. 2005;14:764–7.
9. Schaal C, Chellappan SP. Nicotine-mediated cell proliferation and
tumor progression in smoking-related cancers. Mol Cancer Res.
2014;12:14–23.
Fig. 8 Dextromethorphan and
metformin inhibit CIC
properties in ESCC. Nicotine



















Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting. . .
10. Mineur YS, Picciotto MR. Nicotine receptors and depression:
revisiting and revising the cholinergic hypothesis. Trends Phar-
macol Sci. 2010;31:580–6.
11. Li H, Wang S, Takayama K, Harada T, Okamoto I, Iwama E, et al.
Nicotine induces resistance to erlotinib via cross-talk between
alpha 1 nAChR and EGFR in the non-small cell lung cancer
xenograft model. Lung Cancer. 2015;88:1–8.
12. Hallden S, Sjogren M, Hedblad B, Engstrom G, Hamrefors V,
Manjer J, et al. Gene variance in the nicotinic receptor cluster
(CHRNA5-CHRNA3-CHRNB4) predicts death from cardio-
pulmonary disease and cancer in smokers. J Intern Med.
2016;279:388–98.
13. Improgo MR, Scofield MD, Tapper AR, Gardner PD. The nico-
tinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual
role in nicotine addiction and lung cancer. Prog Neurobiol.
2010;92:212–26.
14. Paleari L, Negri E, Catassi A, Cilli M, Servent D, D’Angelillo R,
et al. Inhibition of nonneuronal alpha7-nicotinic receptor for lung
cancer treatment. Am J Respir Crit Care Med. 2009;179:1141–50.
15. Egleton RD, Brown KC, Dasgupta P. Nicotinic acetylcholine
receptors in cancer: multiple roles in proliferation and inhibition of
apoptosis. Trends Pharmacol Sci. 2008;29:151–8.
16. Al-Wadei MH, Banerjee J, Al-Wadei HA, Schuller HM. Nicotine
induces self-renewal of pancreatic cancer stem cells via
neurotransmitter-driven activation of sonic hedgehog signalling.
Eur J Cancer. 2016;52:188–96.
17. Nimmakayala RK, Seshacharyulu P, Lakshmanan I, Rachagani S,
Chugh S, Karmakar S, et al. Cigarette smoke induces stem cell
features of pancreatic cancer cells via PAF1. Gastroenterology.
2018;155:892–908 e896.
18. Guha P, Bandyopadhyaya G, Polumuri SK, Chumsri S, Gade P,
Kalvakolanu DV, et al. Nicotine promotes apoptosis resistance of
breast cancer cells and enrichment of side population cells with
cancer stem cell-like properties via a signaling cascade involving
galectin-3, alpha9 nicotinic acetylcholine receptor and STAT3.
Breast Cancer Res Treat. 2014;145:5–22.
19. Dong H, Xu J, Li W, Gan J, Lin W, Ke J, et al. Reciprocal
androgen receptor/interleukin-6 crosstalk drives oesophageal car-
cinoma progression and contributes to patient prognosis. J Pathol.
2017;241:448–62.
20. Xiong X, Ke X, Wang L, Yao Z, Guo Y, Zhang X, et al. Splice
variant of growth hormone-releasing hormone receptor drives
esophageal squamous cell carcinoma conferring a therapeutic
target. Proc Natl Acad Sci USA. 2020;117:6726–32.
21. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Met-
formin promotes autophagy and apoptosis in esophageal squa-
mous cell carcinoma by downregulating Stat3 signaling. Cell
Death Dis. 2014;5:e1088.
22. Lin Y, Dong H, Deng W, Lin W, Li K, Xiong X, et al. Evaluation
of salivary exosomal chimeric GOLM1-NAA35 RNA as a
potential biomarker in esophageal carcinoma. Clin Cancer Res.
2019;25:3035–45.
23. Momi N, Ponnusamy MP, Kaur S, Rachagani S, Kunigal SS,
Chellappan S, et al. Nicotine/cigarette smoke promotes metastasis
of pancreatic cancer through alpha7nAChR-mediated MUC4
upregulation. Oncogene. 2013;32:1384–95.
24. Parada E, Egea J, Romero A, del Barrio L, Garcia AG, Lopez MG.
Poststress treatment with PNU282987 can rescue SH-SY5Y cells
undergoing apoptosis via alpha7 nicotinic receptors linked to a
Jak2/Akt/HO-1 signaling pathway. Free Radic Biol Med.
2010;49:1815–21.
25. Bridgeman SC, Ellison GC, Melton PE, Newsholme P, Mamotte
CDS. Epigenetic effects of metformin: from molecular mechan-
isms to clinical implications. Diabetes Obes Metab.
2018;20:1553–62.
26. Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, et al. Reg-
ulation of tumor cell migration and invasion by the H19/let-7 axis
is antagonized by metformin-induced DNA methylation. Onco-
gene. 2015;34:3076–84.
27. Cuyas E, Fernandez-Arroyo S, Verdura S, Garcia RA, Stursa J,
Werner L, et al. Metformin regulates global DNA methylation via
mitochondrial one-carbon metabolism. Oncogene. 2018;37:963–70.
28. Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, et al. Metformin
induces human esophageal carcinoma cell pyroptosis by targeting
the miR-497/PELP1 axis. Cancer Lett. 2019;450:22–31.
29. Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, et al. Low-
dose metformin reprograms the tumor immune microenvironment
in human esophageal cancer: results of a phase II clinical trial.
Clin Cancer Res. 2020;26:4921–32.
30. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser
ES, et al. Persistent epigenetic differences associated with prenatal
exposure to famine in humans. Proc Natl Acad Sci USA.
2008;105:17046–9.
31. Wright MJ Jr., Vann RE, Gamage TF, Damaj MI, Wiley JL.
Comparative effects of dextromethorphan and dextrorphan on
nicotine discrimination in rats. Pharm Biochem Behav.
2006;85:507–13.
32. Damaj MI, Flood P, Ho KK, May EL, Martin BR. Effect of
dextrometorphan and dextrorphan on nicotine and neuronal
nicotinic receptors: in vitro and in vivo selectivity. J Pharmacol
Exp Ther. 2005;312:780–5.
33. Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, et al. Acylglycerol
kinase augments JAK2/STAT3 signaling in esophageal squamous
cells. J Clin Investig. 2013;123:2576–89.
34. Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, et al.
Metformin alters DNA methylation genome-wide via the H19/
SAHH axis. Oncogene. 2017;36:2345–54.
35. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose
oral dextromethorphan versus placebo in painful diabetic neuropathy
and postherpetic neuralgia. Neurology. 1997;48:1212–8.
36. Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP,
Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-
quinidine on agitation in patients with Alzheimer disease
dementia: a randomized clinical trial. JAMA. 2015;314:1242–54.
37. Martin E, Morel V, Joly D, Villatte C, Delage N, Dubray C, et al.
Rationale and design of a randomized double-blind clinical trial in
breast cancer: dextromethorphan in chemotherapy-induced per-
ipheral neuropathy. Contemp Clin Trials. 2015;41:146–51.
38. Sang CN, Booher S, Gilron I, Parada S, Max MB. Dex-
tromethorphan and memantine in painful diabetic neuropathy and
postherpetic neuralgia: efficacy and dose-response trials. Anes-
thesiology. 2002;96:1053–61.
L. Wang et al.
